Compare Flux Power Holdings Inc (FLUX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Merck & Co., Inc. — how do they compare? Flux Power Holdings Inc trades at $0.48 (market cap $9.97M), while Merck & Co., Inc. trades at $144.66 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 35233.7× Flux Power Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and Merck & Co., Inc. for 98 Days on average.
| FLUX | MRK | |
|---|---|---|
Market Cap | $9.97M | $351.28B |
Volume | 817,320 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $6.66 | $156.43 |
52-Week Low | $0.41 | $82.49 |
Typical Hold Time | 20 Days | 98 Days |
Enterprise Value | $18.18M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.49, down 0.55% today, amid ongoing acquisition interest from Solidion Technology. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $66M in 2025 to $42M in 2026 and persistent net losses. Despite unanimous analyst buy ratings, recent earnings misses and negative profitability metrics (-17.68% net margin) highlight operational challenges.
The outlook remains speculative with acquisition potential offering upside, but fundamental weakness and cash flow concerns pose significant risks. Investors face a binary outcome between takeover premium and continued operational losses in the competitive energy storage sector.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
